2016
Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors
Hong J, Kwon Y, Kim I. Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors. Expert Opinion On Drug Metabolism & Toxicology 2016, 13: 183-192. PMID: 27690667, DOI: 10.1080/17425255.2017.1244265.Peer-Reviewed Original ResearchConceptsErectile dysfunctionClinical efficacyEvidence-based clinical efficacyTreatment of EDNon-urological conditionsDrug-related toxicityFirst-line drugsType 5 inhibitorsPhosphodiesterase-5 inhibitorsNew clinical usesChronic administrationBasic science articlesNeuroprotective roleClinical trialsPDE5IsBeneficial effectsClinical usesFurther studiesPharmacodynamicsPharmacokineticsEfficacyInhibitorsImpactful studiesBroad spectrumPDE5i
2013
Comprehensive Analysis of Sexual Function Outcome in Prostate Cancer Patients After Robot-Assisted Radical Prostatectomy
Woo S, Kang D, Ha Y, Salmasi A, Kim J, Lee D, Kim W, Kim I. Comprehensive Analysis of Sexual Function Outcome in Prostate Cancer Patients After Robot-Assisted Radical Prostatectomy. Journal Of Endourology 2013, 28: 172-177. PMID: 23987521, DOI: 10.1089/end.2013.0304.Peer-Reviewed Original ResearchConceptsRobot-assisted radical prostatectomyPotency ratesNeurovascular bundleRadical prostatectomyPotency recoveryBilateral preservationYounger ageOverall potencyPhosphodiesterase type 5 inhibitorsBaseline erectile functionPreoperative potency statusSexual Health InventoryDatabase of patientsType 5 inhibitorsFunction 12 monthsProstate cancer patientsRecovery of potencySexual function outcomesPDE-5 inhibitorsOverall potency rateMultivariate regression analysisPotency statusPreoperative potencyErectile functionIndependent predictors